Home Cart Sign in  
Chemical Structure| 853220-52-7 Chemical Structure| 853220-52-7

Structure of BML-284
CAS No.: 853220-52-7

Chemical Structure| 853220-52-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BML-284 is a Wnt signaling activator with EC50 value of 0.7 μM for inducing β-catenin and TCF-dependent transcriptional activity.

Synonyms: Wnt Agonist I

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BML-284

CAS No. :853220-52-7
Formula : C19H18N4O3
M.W : 350.37
SMILES Code : NC1=NC(C2=CC=CC(OC)=C2)=CC(NCC3=CC=C(OCO4)C4=C3)=N1
Synonyms :
Wnt Agonist I
MDL No. :MFCD09908087
InChI Key :FABQUVYDAXWUQP-UHFFFAOYSA-N
Pubchem ID :11210285

Safety of BML-284

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse bone marrow macrophages (BMMs) 50 μg/mL 3 days Inhibit osteoclast differentiation of BMMs Mater Today Bio. 2022 Oct 10;17:100458
Human umbilical vein endothelial cells (HUVECs) 50 μg/mL 7 days Promote angiogenic activity of HUVECs Mater Today Bio. 2022 Oct 10;17:100458
MC3T3-E1 cells 50 μg/mL 7 days Promote osteogenic differentiation of MC3T3-E1 cells Mater Today Bio. 2022 Oct 10;17:100458
JAR cells 5 µM BML-284, as a β-catenin activator, was used to study the mechanism by which RASAL1 modulates tumorigenicity and chemoresistance via β-catenin. Results showed that BML-284 could partially reverse the inhibitory effect of 5-Aza on β-catenin in JAR cells. BMC Cancer. 2024 Aug 8;24(1):977
SVF adipocytes 10 mM 4 days BML-284 treatment led to disappearance of lipid droplets and elongated cell morphology, significantly reducing the expression of adipogenic genes while increasing the expression of pluripotency marker genes. Stem Cell Res Ther. 2023 Dec 20;14(1):333
3T3-L1 adipocytes 10 mM 4 days BML-284 treatment led to disappearance of lipid droplets and elongated cell morphology, significantly reducing the expression of adipogenic genes (C/EBPβ, PPAR-γ, and adiponectin) while increasing the expression of pluripotency marker genes (Smad9, Esrrb, and Sox2). Stem Cell Res Ther. 2023 Dec 20;14(1):333
RCT-FAPs 1 μM 7 days BML-284 increased β-catenin activity and decreased PPARγ protein expression, limiting adipogenic differentiation of FAPs. Cell Death Discov. 2023 Aug 25;9(1):312

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.29mL

14.27mL

2.85mL

1.43mL

28.54mL

5.71mL

2.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories